Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05368103
Other study ID # HZNP-DAX-201
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date April 27, 2022
Est. completion date January 25, 2024

Study information

Verified date February 2024
Source Amgen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the preliminary efficacy, safety, tolerability, PK, and PD of Daxdilimab in participants with moderate to severe AA, with ≥50% and ≤95% total scalp hair loss as defined by the SALT score at Screening and Day 1.


Description:

Approximately 30 participants will be enrolled to receive daxdilimab administered subcutaneously over 32 weeks. The maximum trial duration per participant is approximately 52 weeks, including up to 30 days for the screening period, 32 weeks for the open-label treatment period where participants will receive daxdilimab and approximately 16 weeks for the follow-up period. Safety evaluations will be performed regularly throughout the course of the study. Study acquired from Horizon in 2024.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date January 25, 2024
Est. primary completion date August 7, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Willing and able to give informed consent. 2. Willing and able to comply with the prescribed treatment protocol and evaluations for the duration of the trial. 3. Adult men or women 18 to 65 years of age. 4. Willing to keep the same hair style and color (eg, hair products, process, and timing for hair appointments) for the duration of the trial. 5. Clinical diagnosis of moderate-to-severe AA - defined as meeting the following criteria: - Presence of = 50% and = 95% total scalp hair loss at screening and baseline (Day 1) defined by the SALT score. - Duration of current episode of hair loss >3 months but <7 years at screening and Day 1, along with investigators' assessment that hair regrowth is possible. - No evidence of active regrowth present at baseline and no known history of significant regrowth, as per investigator's judgement, over the last 6 months. Exclusion Criteria: 1. Individuals involved in the conduct of the trial, their employees, or immediate family members of such individuals. 2. Any clinically significant medical condition or physical/laboratory/ECG/vital signs abnormality that would, in the opinion of the investigator, put the participant at undue risk or interfere with the evaluation of the IP or interpretation of trial results. 3. History of allergy, hypersensitivity reaction, or anaphylaxis to any component of the IP or to a previous monoclonal antibody (mAb) or human immunoglobulin (Ig) therapy. 4. Participant has had excessive sun exposure, is planning a trip to a sunny climate, or has used tanning booths within 4 weeks prior to Day 1 or is not willing to minimize natural and artificial sunlight exposure during the trial. Use of sunscreen products and protective apparel are recommended when sun exposure cannot be avoided. 5. Known history of a primary immunodeficiency or an underlying condition such as known human immunodeficiency virus (HIV) infection, a positive result for HIV infection, splenectomy, or any underlying condition that in the opinion of the investigator significantly predisposes the participant to infection. 6. Confirmed positive test for hepatitis B serology defined as: - Hepatitis B surface antigen (HBsAg), or - Hepatitis B core antibody (HBcAb or anti-HBc) 7. Positive test for hepatitis C virus antibody. 8. Active tuberculosis (TB), or a positive TB test at Screening. Participant will be evaluated for latent TB infection with a purified protein derivative (PPD) test or a QuantiFERON-TB Gold test. Participants who demonstrate evidence of latent TB infection (either PPD =5 mm of induration or positive QuantiFERON-TB Gold test, irrespective of bacille Calmette-Guérin vaccination status will not be allowed to participate in the trial, unless documented history of appropriate treatment for active or latent TB. Participants with an indeterminate test result can repeat the test, but if the repeat test is also indeterminate, they are excluded. 9. Any severe herpes virus family infection (including Epstein-Barr virus, cytomegalovirus [CMV]) at any time prior to Day 1, including, but not limited to, disseminated herpes, herpes encephalitis, recent recurrent herpes zoster (defined as 2 episodes within the last 2 years), or ophthalmic herpes. 10. Any herpes zoster, CMV, or Epstein-Barr virus infection that was not completely resolved 12 weeks prior to Day 1. 11. Any of the following within 30 days prior to signing the ICF and though Day 1: - Clinically significant active infection in the opinion of the investigator, including ongoing, and chronic infection requiring antibiotics or antiviral medication (chronic nail infections are allowed). Note: Participant with a limited recurrence of a cold sore or herpes genitalis between ICF signature and Day 1 could be eligible based on the investigator's judgement. - Any infection requiring hospitalization or treatment with intravenous (IV) anti-infectives. - A participant with a documented positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test may be rescreened at least 2 weeks after a positive test if the participant is asymptomatic and at least 3 weeks after resolution of symptomatic Coronavirus Disease 2019 (COVID-19) illness. 12. Opportunistic infection requiring hospitalization or parenteral antimicrobial treatment within 2 years prior to Day 1. 13. Any acute illness or evidence of clinically significant active infection, such as fever = 38.0°C (= 100.5°F) on Day 1. 14. History of clinically significant cardiac disease including unstable angina; myocardial infarction within 6 months prior to Day 1; congestive heart failure; arrhythmia requiring active therapy, except for clinically insignificant extra systoles, or minor conduction abnormalities; or presence of clinically significant abnormality on ECG if, in the opinion of the investigator, it would increase the risk of trial participation. 15. History of cancer or lymphoproliferative disease within 5 years prior to Day 1, except as follows: - In situ carcinoma of the cervix treated with apparent success with curative therapy > 12 months prior to Screening, or - Nonmetastatic cutaneous basal cell or squamous cell carcinoma of the skin treated with apparent success with curative therapy. 16. Active forms of other inflammatory skin disease(s) or evidence of other skin conditions (eg, psoriasis, seborrheic dermatitis, lupus) at the time of the Screening and through Day 1, that in the opinion of the investigator might interfere with evaluation of AA and the assessment of the activity measures. 17. Presence of another form of alopecia (except for androgenic alopecia). 18. History of male or female pattern hair loss > Hamilton stage III or > Ludwig stage II. 19. History or presence of hair transplants. 20. History or presence of micropigmentation of the scalp (Note: microblading of the eyebrows is permitted). 21. Use of steroids (systemic and intralesional), anthralin, squaric acid, diphenylcycloprophenone (DPCP), dinitrochlorobenzene (DCNB), protopic, minoxidil, or any other medication which in the opinion of the investigator may affect hair regrowth within 4 weeks of Day 1 visit. Note: Intranasal and inhaled corticosteroids are allowed, eye and ear drops containing corticosteroids are also allowed. 22. Use of platelet-rich plasma injections in the last 12 weeks prior to Day 1. 23. Topical medicated treatment that could affect AA including, but not limited to, topical corticosteroids, calcineurin inhibitors, antimicrobials, medical devices within 2 weeks of Day 1 visit. Note: Topical corticosteroids are permitted outside of the scalp, eyebrows, and eyelids. 24. Participants who have had previous treatment with any biologic B-cell-depleting therapy (eg, rituximab, ocrelizumab, or ofatumumab) or other B-cell targeting therapy (eg, belimumab) within 12 months before Day 1. 25. Participants who have received previous treatment with pDC inhibiting therapies (eg, anti-ILT7, anti-blood dendritic cell antigen 2 [BDCA2]). 26. Inadequate response to adequate trial of oral Janus Kinase (JAK) inhibitors. Previous exposure to topical JAK inhibitors is acceptable, regardless of response. 27. Any biologic or conventional disease-modifying antirheumatic drugs (DMARD), immunosuppressant (eg, cyclosporine, methotrexate, or azathioprine), JAK-inhibitors, interferon (IFN) blocking therapies, or antiproliferative agents, if last dose was taken: a. within 8 weeks prior to Day 1 or b. drug-specific 5 half-lives elimination period (if longer than 8 weeks). 28. Participant has received any marketed or investigational biological agent within 12 weeks or 5 half-lives (whichever is longer) prior to Day 1. 29. Currently receiving a nonbiological IP or device or has received one within 4 weeks prior to Day 1 or within 5 published half-lives, whichever is longer. 30. Participant has received any ultraviolet (UV)-B phototherapy (including tanning beds), has had psoralen-UV-A (PUVA) treatment, or excimer laser within 4 weeks prior to Day 1.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Daxdilimab
Daxdilimab will be administered subcutaneously as two injections for each dose.

Locations

Country Name City State
Canada Dr Dusan Sajic Medicine Professional Corporation Guelph Ontario
Canada Lynderm Research Inc. Markham Ontario
Canada Innovaderm Research Montréal Quebec
Canada The Centre for Clinical Trials Oakville Ontario
Canada SKiN Centre for Dermatology Peterborough Ontario
Canada Centre de Recherche Saint-Louis (Quebec) Quebec
Canada Enverus Medical Research Surrey British Columbia
United States First OC Dermatology Research, Inc. Fountain Valley California
United States Burke Pharmaceutical Research Hot Springs Arkansas
United States DS Research Louisville Kentucky
United States Progressive Clinical Research, P.A. San Antonio Texas
United States Dermatology Specialists of Spokane Spokane Washington
United States ForCare Clinical Research Tampa Florida

Sponsors (1)

Lead Sponsor Collaborator
Amgen

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percent change from baseline in Severity of Alopecia Tool (SALT) score at Week 24. Day 1 through Week 24.
Secondary Percent change from baseline in Severity of Alopecia Tool (SALT) score at Weeks 12-20; 28-36. Weeks 12-20; 28-36
Secondary Proportion of participants who achieve =50% reduction in Severity of Alopecia Tool (SALT) from baseline at Weeks 12-36. Weeks 12-36
Secondary Proportion of participants with absolute Severity of Alopecia Tool (SALT) score = 10, 20, 30, 50 at Weeks 12-36. Weeks 12-36
Secondary Percent change from baseline in Severity of Alopecia Tool (SALT) score at Weeks 40-48. Weeks 40-48
Secondary Proportion of participants who achieve =50% reduction in Severity of Alopecia Tool (SALT) from baseline at Weeks 40-48. Weeks 40-48
Secondary Proportion of participants with absolute Severity of Alopecia Tool (SALT) score = 10, 20, 30, 50 at Weeks 40-48. Weeks 40-48
Secondary Change from baseline in plasmacytoid dendritic cells (pDCs). Day 1 to 48 Weeks
Secondary Anti-drug antibody (ADA) rate. Day 1 to 48 Weeks
Secondary Incidence of treatment-emergent adverse events (TEAEs), treatment-serious adverse events (TESAEs), and adverse events of special interest (AESIs). Day 1 to 48 Weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05051761 - Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata Phase 3
Active, not recruiting NCT03570749 - A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata Phase 2/Phase 3
Completed NCT02812342 - Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants Phase 2
Completed NCT02350023 - Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata Phase 4
Completed NCT02018042 - An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata Phase 2
Terminated NCT01898806 - Intralesional Steroids in the Treatment of Alopecia Areata Phase 4
Recruiting NCT04011748 - Clinical Application of Stem Cell Educator Therapy in Alopecia Areata Phase 2
Terminated NCT04517864 - PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA Phase 2
Not yet recruiting NCT05803070 - Topical Cetirizine in Treatment of Localized Alopecia Areata
Not yet recruiting NCT05496426 - A Study of KL130008 in Adults With Severe Alopecia Areata Phase 2
Completed NCT04147845 - Transepidermal Delivery of Triamcinolone Acetonide or Platelet Rich Plasma Using Either Fractional Carbon Dioxide Laser or Microneedling in Treatment of Alopecia Areata N/A
Terminated NCT03325296 - Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata. Phase 2
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Enrolling by invitation NCT05745389 - CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry
Recruiting NCT04246372 - Tofacitinib for Immune Skin Conditions in Down Syndrome Phase 2
Not yet recruiting NCT06087796 - Topical Pentoxifylline; Metformin Versus Betamethasone in the Treatment of Alopecia Areata. Phase 1
Withdrawn NCT03532958 - Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata Phase 2
Recruiting NCT02604888 - Efficacy Study of a Cosmetic Lotion in the Treatment of Alopecia Areata in Males and Females N/A
Terminated NCT01385839 - Efficacy of Hair Transplantation Compared With Hypodermic Needle Irritation in Alopecia Areata N/A
Completed NCT00408798 - Treatment of Alopecia Areata of the Scalp With Intradermal Injections of Botulinum Toxin N/A